

## **THERASPHERE™** Y-90 Microspheres


# **A LEAP IN LIVER TUMOR THERAPY?**

Radiation Segmentectomy with TheraSphere - a precise way to selectively target tumors in patients with early HCC



Radiation segmentectomy is the application of a selective ablative dose of Yttrium-90 radiation with glass microspheres to tumors, usually delivered to no more than two hepatic segments<sup>1</sup>

- ✓ Reproducible catheter-based technique<sup>1,2</sup>
- ✓ TheraSphere is delivered directly to the tumor-bearing segment with a target dose of  $>190 \text{ Gy}^2$
- ✓ Results in higher dose(s) to the segment producing excellent radiation tumor coverage and low clinical toxicity<sup>1</sup>



“Radiation segmentectomy was found to generate outcomes consistent with treatments considered to be curative (RFA, resection and transplant)”


- Lewandowski et al. 2018

## High Rates of Complete Pathologic Necrosis (CPN)<sup>3</sup>


### Solitary HCC ≤5cm

- All transplanted patients (n=33) had 90-100% pathologic necrosis
- More CPN observed with target dose of >190 Gy to the treatment area

Dose to the liver does not exceed 150 Gy




Angiography: Segment 4 lesion where radiation segmentectomy was performed with 300 Gy



16-month follow-up: Complete tumor necrosis (mRECIST). No viable tumor at explant

## Favorable Survival Outcomes Comparable to RFA, Resection and Transplant<sup>1</sup>

Median overall survival (n=70) of 6.7 years



## Superior Outcomes vs TACE


Improved imaging response and longer time to second treatment compared to TACE<sup>5</sup>

Solitary HCC ≤3cm



Superior progression-free survival, higher complete response and better local tumor control rates compared to TACE<sup>4</sup>

Child Pugh A-C with treatment region equivalent to single hepatic Couinaud segment



The safety and effectiveness of TheraSphere in HCC patients with Child-Pugh B and C liver function have not been established.

Reprinted from Hepatology, Vol 60/edition 1, Michael Vouche, Ali Habib, Thomas J. Ward, pages 199-201, July 2014, with permission from Wiley.

CPN: Complete pathologic necrosis; HCC: Hepatocellular carcinoma; RFA: radiofrequency ablation; RS: Radiation segmentectomy; TACE: Transarterial chemoembolization

References 1. Lewandowski RJ, Gabr A, Abouchaleh N et al. Radiology 2018; 287(3). <https://doi.org/10.1148/radiol.2018171768>. 2. Riaz A, Gates VL, Atassi B et al. Int J Radiat Oncol Biol Phys 2011; 79(1): 163-71. 3. Vouche M, Habib A, Ward TJ et al. Hepatology 2014; 60(1): 192-201. 4. Padia SA, Johnson GE, Horton KI et al. J Vasc Interv Radiol 2017; 28(6): 777-85.e1. 5. Biederman DM, Titano JJ, Korff RA, et al. J Vasc Interv Radiol 2018; 29: 30-37.e2.

### TheraSphere® Yttrium-90 Glass Microspheres

**INDICATION FOR USE:** TheraSphere is indicated for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm in diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status. **CONTRAINDICATIONS:** TheraSphere is contraindicated in patients whose Tc-99m macroaggregated albumin (MAA) hepatic arterial perfusion scintigraphy shows any deposition to the gastrointestinal tract that may not be corrected by angiographic techniques • who show shunting of blood to the lungs that could result in delivery of greater than 16.5 mCi (0.61 GBq) of Y-90 to the lungs. Radiation pneumonitis has been seen rarely in patients receiving doses to the lungs greater than 30 Gy in a single treatment. • in whom hepatic artery catheterization is contraindicated, such as patients with vascular abnormalities or bleeding diathesis • who have pulmonary insufficiency (conventionally defined by an arterial oxygen pressure (PaO<sub>2</sub>) of <60 mmHg or oxygen saturation (SaO<sub>2</sub>) of <90%) or severe liver dysfunction, including hepatic encephalopathy, clinically evident ascites or treatment with diuretics for ascites • with portal vein thrombosis (PVT) Type 4 involvement and lack of Tc-99m MAA deposition on the PVT seen on the Tc-99m MAA imaging with >70% tumor replacement in the liver • with comorbidities or poor overall health (e.g., ECOG performance status rating > 2) which may make the patient a poor candidate for locoregional radiation treatment. • who are pregnant. **WARNINGS:** The following pre-treatment, high-risk factors (disease characteristics) have been associated with serious adverse events deemed possibly related to use of the device: infiltrative tumor type • tumor nodules too numerous to count • AST or ALT > 5 times ULN • bilirubin > 2 mg/dL • tumor volume > 50% combined with albumin < 3 g/dL. Keep the TheraSphere dose vial upright and stored in its lead pot before and during patient treatment, except as required for radiation measurement. Do not open the dose vial acyclic shield prior to patient treatment. Post-treatment, waste materials require caution to prevent contamination and beta shielding due to residual glass microspheres. **PRECAUTIONS: GENERAL: PRECAUTIONS:** As in any intra-arterial procedure, aseptic technique should be practiced, and care should be taken to ensure minimum patient anesthesia exposure extraneous to the therapeutic objective. • Consideration of patient comorbidities should be used when determining the type and volume of fluid to infuse via catheter to avoid electrolyte imbalance, fluid shift, and hyperglycemia. • It is important to avoid any aggressive arterial procedure that may lead to arterial spasm that impairs TheraSphere distribution into the perfused liver target volume which may lead to underdose or non-target deposition of TheraSphere. **PRECAUTION IN PATIENTS WITH IMPAIRED LIVER FUNCTION:** No efficacy or safety data from the LEGACY study are available to support the use of the device in patients with Child-Pugh score B or C cirrhosis. **PRECAUTION IN VULNERABLE PATIENTS:** No effectiveness or safety data are available to support the use of the device in children or breast-feeding women. **ENDOCRINE DISRUPTION, CARCINOGENICITY, MUTAGENICITY, TOXICITY TO REPRODUCTION:** Ideally the use of this radioactive device in women of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses. **RADIATION SAFETY:** Radioactive products should be used only by healthcare professionals who are qualified by specific training in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides. • As in the use of any radioactive material, ensure minimum radiation exposure to the patient, entourage, and to minimize radiation exposure to workers and others in contact with the patient. **RELEASE AND POST-TREATMENT PRECAUTIONS:** Post-treatment patient care: use universal precautions for body fluid contact. Trace Y-90 may be detectable in blood and urine; handle with gloves and dispose as normal body fluids. The radiation field is expected to be less than 1 mrem/h (10 μSv/h) at 3 ft (1 m) from the patient's abdomen. Supplemental shielding and segregation of the patient are not required to maintain exposure to others below regulated limits. • Release instructions: The patient should follow good hygiene (e.g., proper hand washing). Caregivers, family, and others do not require restrictions on patient contact; however, they can minimize their radiation exposure by avoiding prolonged time (>12 hours per day) within 1 ft (0.3 m) of the patient's abdomen for the first week post therapy. Patients should be advised that radiation emitted from the patient may be detectable at security screening (e.g., international travel). • Special precautions post-administration: If the patient requires hospitalization, surgery, medical assessment or treatment regarding any part of their thorax or abdomen within first 2 weeks of treatment, the patient should advise the hospital and treating physician of the Y-90 TheraSphere implant. The physician should consult their radiation safety staff for handling and disposal of liver tissue. • Special liver tissue handling: Special liver tissue handling may be required for post-treatment surgery, explant, or transplant since the glass microspheres remain permanently implanted in the liver tissue. Disclosure of the treatment will be required if cremation is considered. **POTENTIAL ADVERSE EVENTS:** The use of this product leads to irradiation of both tumorous and normal liver tissue. As a result, patients with compromised liver function may be at greater risk of liver function impairment and hence could experience complications. Clinical side effects usually occur within the first 4 to 6 weeks after treatment. Based on clinical trial data, literature reviews and post market surveillance, adverse events potentially associated with treatment using Y-90 microspheres, including TheraSphere, may include the following: Allergic reaction • Altered liver function, acute or chronic • Anorexia • Anxiety • Ascites • Bile Duct injury • Bleeding/hemorrhage • Chills/rigors • Cholecystitis (inflammatory or infectious) • Colitis • Death • Dehydration • Diarrhea • Dizziness • Dyspnea • Edema (any location) • Electrolyte abnormalities • Elevated BUN/creatinine • Fall • Fatigue • Fever • Gastrointestinal bleeding/hemorrhage • Hemorrhage • Gastrointestinal ulcer or ulceration • Hepatic encephalopathy • Hepatorenal failure • Hypocapnia • Hypertension • Hypotension • Infection (any location) • Liver failure, acute or chronic • Lymphopenia • Malaise • Mood alteration • Muscle weakness • Nausea • Neutropenia • Pain (any location) • Pancreatitis • Platelet count abnormalities • Pleural effusion • Portal hypertension • Pre-existing chronic liver disease decompensation • Pulmonary edema • Pulmonary fibrosis • Radiation hepatitis • Radiation induced disease, acute • Radio Embolization Induced Liver Disease (REILD) • Sepsis • Supraventricular arrhythmia • Thrombosis (arterial or venous) • Tumor inflammation (including tumor edema) • Tumor-lysis syndrome • Vomiting • Weight loss. Complications related to the administration procedure itself may include: Allergic reaction: Arterial injury including vessel dissection • Aspiration pneumonia • Bursitis/bleeding/hematoma at site • Constipation/abdominal distension • Fatigue • Flushing • Infection • Nausea • Nerve damage. **CAUTION:** Federal (USA) law restricts this device to sale by or on order of a physician. PI-992004-AA

**Note:** Dose to the liver does not exceed 150 Gy. The physician should always take the above-noted Pre-treatment High Risk Factors into consideration for each patient when making decisions regarding the use of TheraSphere for treatment. TheraSphere is a registered trademark of Theragnostics Corporation used under license by Biocompatibles UK Ltd. All other trademarks are property of their respective owners.

**Boston Scientific**  
Advancing science for life™

**Peripheral Interventions**  
300 Boston Scientific Way  
Marlborough, MA 01752-1234  
[www.bostonscientific.com](http://www.bostonscientific.com)

To order product or for more information  
contact customer service at 1.888.272.1001.

© 2021 Boston Scientific Corporation  
or its affiliates. All rights reserved.

PI-746405-AB